Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Discovery awards Markus Spiske

Disease models which use ‘real world data’ from existing population cohorts can be used to improve efficiency of drug treatment strategies.

The 'Real world Outcomes across the Alzheimer's Disease spectrum for better care initiative' – ROADMAP – was created to facilitate the open collaboration among a variety of stakeholders to efficiently use real world evidence (RWE) for the benefit of patients with Alzheimer’s disease and their carers. The objective of the study is to validate natural disease progression models in people with Alzheimer's disease.

The impact of this research is to build a disease progression model that can be used for the health economic evaluation of the efficiency of different treatment pathways.